Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) (EXCALIBER-RRMM)
*The trial information contained on this page was imported from ClinicalTrials.gov. Click here to view this trial on ClinicalTrials.gov.
- Full Title:
- A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM)
- Myeloma stage or condition:
- Multiple Myeloma
- Study phase:
- Phase 3
- Summary/Purpose:
- This is a multicenter, two-stage, randomized, controlled, open-label, Phase 3 study comparing the efficacy and safety of iberdomide in combination with dexamethasone and daratumumab (IberDd) versus daratumumab, bortezomib, and dexamethasone (DVd) in participants with relapsed or refractory multiple myeloma (RRMM).
- Detailed Description:
- This is a multicenter, two-stage, randomized, controlled, open-label, Phase 3 study comparing the efficacy and safety of iberdomide in combination with dexamethasone and daratumumab (IberDd) versus daratumumab, bortezomib, and dexamethasone (DVd) in participants with relapsed or refractory multiple myeloma (RRMM). Approximately 200 patients randomized in stage 1 to one of three iberdomide dose levels of 1, 1.3, or 1.6 mg in combination with daratumumab and dexamethasone (Treatment Arms A1, A2, or A3), or to the DVd comparator arm (Treatment Arm B). In Stage 2 of the study, approximately 664 additional subjects will be randomized 1:1 between 2 treatment arms: * Approximately 332 subjects will be randomized to receive Treatment Arm A (IberDd) * Approximately 332 subjects will be randomized to receive Treatment Arm B (DVd) Participants in both treatment arms will continue to receive treatment until confirmed progressive disease (PD), unacceptable toxicity or withdrawal of consent. To ensure accuracy and completeness of the primary endpoint assessment of progression-free survival (PFS), participants who permanently discontinue study treatment for any reason, other than confirmed PD or withdrawal of consent, will continue to be followed for disease assessment. The study will be conducted in compliance with International Council for Harmonisation (ICH) and Good Clinical Practices (GCPs).
- Treatments:
- Drug : Dexamethasone
Oral dexamethasone 40mg on days 1, 8, 15, 22 of a 28-day cycle
- Drug : Daratumumab
Subcutaneous Daratumumab 1800mg on Days 1, 8, 15 and 22 for Cycles 1 to 2, on Days 1 and 15 for Cycles 3 to 6, and then on Day 1 for Cycle 7 of a 28-day cycle
- Drug : Bortezomib
Subcutaneous Bortezomib 1.3 mg/m2 on Days 1, 4, 8 and 11 of each 21-day cycle for a total of 8 cycles.
- Drug : Iberdomide
Oral Iberdomide 1.0mg on Days 1 to 21 of a 28-day cycle
- Drug : Iberdomide
Oral Iberdomide 1.3mg on Days 1 to 21 of a 28-day cycle
- Drug : Iberdomide
Oral Iberdomide 1.6mg on Days 1 to 21 of a 28-day cycle
- Study Arms:
- Experimental : Daratumumab in combination with Iberdomide and dexamethasone - Dose 1
Participants will receive oral iberdomide, subcutaneous daratumumab and oral dexamethasone. - Experimental : Daratumumab in combination with Iberdomide and dexamethasone - Dose 2
- Experimental : Daratumumab in combination with Iberdomide and dexamethasone - Dose 3
- Active Comparator : Daratumumab in combination with dexamethasone and bortezomib
Participants will receive subcutaneous daratumumab, bortezomib and oral dexamethasone
- Study Type:
- Interventional
- Study Design:
- Allocation: Randomized
- Intervention Model: Parallel
- Primary Purpose: Treatment
- Masking: None
- Recruitment status:
- Recruiting
- Eligibility criteria:
- eria * Documented diagnosis of multiple myeloma (MM) and measurable disease. * Received 1 to 2 prior lines of anti-myeloma therapy. * Must have documented disease progression during or after their last anti-myeloma regimen. * Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1 or 2. Exclusion Criteria * Any condition that confounds the ability to interpret data from the study. * Has plasma cell leukemia, Waldenstrom's macroglobulinemia or POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes), or clinically significant amyloidosis. * Known central nervous system involvement with MM. * Prior therapy with iberdomide. * Other protocol-defined Inclusion/Exclusion criteria apply.
- Locations / Centres:
-
Local Institution - 111, Calgary, Alberta – Completed
Local Institution - 103, Edmonton, Alberta – Completed
BC Cancer Agency, Fraser Valley Center, Surrey, British Columbia – Recruiting
Local Institution - 104, Saint John, New Brunswick – Completed
Memorial University of NewfoundlandDr. H Bliss Murphy Cancer Center, St John's, Newfoundland and Labrador – Recruiting
Queen Elizabeth Ii Health Sciences Centre, Halifax, Nova Scotia – Recruiting
Local Institution - 109, Ottawa, Quebec – Completed
Local Institution - 107, Saskatoon, Saskatchewan – Completed
CHU de Quebec-Universite Laval, Quebec, – Recruiting
- Contacts:
- Name: BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
Phone: 855-907-3286
Email: [email protected]
- Publications:
- ???
- First posted:
- Not available
- Actual start date:
- 2022-06-23
- Last updated:
- 2024-07-24
- Estimated enrollment:
- 864
- Estimated completion date:
- 2032-06-25
- Estimated primary completion date:
- 2026-03-18
- Condition:
- Multiple Myeloma
- Gender:
- All
- Ages:
- 18 Years-
- Accepts healthy volunteers:
- Not available
- Listed location countries:
- Not available
- NCT number:
- NCT04975997
- Other study ID numbers:
- CC-220-MM-002
- Has Data monitoring committee:
- Yes
- U.S. FDA-regulated product:
- Yes
- IPD Sharing Statement :
- ???
- Responsible party:
-
Sponsor
- Study sponsor:
- lead_sponsor
Celgene
Industry
- Collaborators:
- ???
- Investigators:
- Bristol-Myers Squibb Bristol-Myers Squibb
- Protocol Registration and Results System:
- ???
- Verification date:
- 2024-07-01